We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
- Authors
DuBois, Steven G; Messina, Julia; Maris, John M; Huberty, John; Glidden, David V; Veatch, Janet; Charron, Martin; Hawkins, Randall; Matthay, Katherine K
- Abstract
Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) has been shown to be active against refractory neuroblastoma. The primary toxicity of (131)I-MIBG is myelosuppression, which might necessitate autologous hematopoietic stem-cell transplantation (AHSCT). The goal of this study was to determine risk factors for myelosuppression and the need for AHSCT after (131)I-MIBG treatment.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Vol 22, Issue 12, p2452
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2004.08.058